Scarica l'app Stockscreener
25.85
0.31%
0.08
Dopo l'orario di chiusura:
25.60
-0.25
-0.97%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SMMT Giù?
Forum
Previsione
Precedente Chiudi:
$25.77
Aprire:
$25.48
Volume 24 ore:
1.76M
Relative Volume:
0.45
Capitalizzazione di mercato:
$19.20B
Reddito:
$956.00K
Utile/perdita netta:
$-221.32M
Rapporto P/E:
-80.78
EPS:
-0.32
Flusso di cassa netto:
$-142.25M
1 W Prestazione:
+8.29%
1M Prestazione:
-22.21%
6M Prestazione:
+36.05%
1 anno Prestazione:
+498.38%
Intervallo 1D:
$25.12
$26.17
Intervallo di 1 settimana:
$22.85
$26.85
Portata 52W:
$2.10
$36.91
Summit Therapeutics Inc Stock (SMMT) Company Profile
Nome
Summit Therapeutics Inc
Settore
Industria
Telefono
305-203-2034
Indirizzo
601 BRICKELL KEY DRIVE, MIAMI
Confronta SMMT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SMMT
Summit Therapeutics Inc
|
25.85 | 17.73B | 956.00K | -221.32M | -142.25M | -0.32 |
|
ONC
Beigene Ltd Adr
|
241.43 | 27.03B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
436.00 | 112.64B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.335 | 40.86M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
588.34 | 64.17B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
75.06 | 6.07B | 0 | -153.72M | -103.81M | -2.00 |
Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-26 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-03-21 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-03-12 | Iniziato | Evercore ISI | Outperform |
| 2025-02-28 | Iniziato | Goldman | Buy |
| 2025-01-08 | Iniziato | Truist | Buy |
| 2024-12-11 | Iniziato | Wells Fargo | Overweight |
| 2024-12-06 | Iniziato | Jefferies | Buy |
| 2024-11-04 | Iniziato | JMP Securities | Mkt Outperform |
| 2024-09-27 | Downgrade | Citigroup | Buy → Neutral |
| 2024-08-12 | Iniziato | H.C. Wainwright | Buy |
| 2024-05-07 | Iniziato | Citigroup | Buy |
| 2024-03-26 | Iniziato | Stifel | Buy |
| 2018-06-28 | Downgrade | Janney | Buy → Neutral |
| 2018-05-02 | Iniziato | Janney | Buy |
| 2018-04-12 | Reiterato | Needham | Buy |
| 2018-02-13 | Iniziato | BTIG Research | Buy |
| 2018-01-04 | Iniziato | SunTrust | Buy |
| 2017-12-01 | Ripresa | H.C. Wainwright | Buy |
| 2016-11-16 | Reiterato | RBC Capital Mkts | Outperform |
| 2016-10-05 | Reiterato | Needham | Buy |
| 2016-09-16 | Iniziato | H.C. Wainwright | Buy |
| 2015-03-30 | Iniziato | Needham | Buy |
| 2015-03-30 | Iniziato | Oppenheimer | Outperform |
Mostra tutto
Summit Therapeutics Inc Borsa (SMMT) Ultime notizie
3 High-Flying Stocks That Could Soar Even More - Nasdaq
Summit Therapeutics (NasdaqGM:SMMT) Reports US$63M Net Loss For Q1 2025 - Yahoo Finance
Summit Therapeutics (SMMT) Receives Buy Rating and $33 Target | - GuruFocus
Summit Therapeutics (SMMT) Receives Buy Rating from Clear Street - GuruFocus
Prediction: These Could Be the Best-Performing Healthcare Stocks Through 2030 - The Globe and Mail
Summit Therapeutics reports inducement grants - Medical Buyer
Got $100? 3 Top Growth Stocks to Buy That Could Double Your Money - Yahoo Finance
(SMMT) Trading Report - news.stocktradersdaily.com
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listi - GuruFocus
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SMMT Stock News - GuruFocus
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - marketscreener.com
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
BioNTech says bispecific antibody BNT327 is competitive against Summit's ivonescimab (BNTX:NASDAQ) - Seeking Alpha
Dimensional Fund Advisors LP Acquires 160,592 Shares of Summit Therapeutics Inc. (NASDAQ:SMMT) - Defense World
Summit Therapeutics Inc. (NASDAQ:SMMT) Receives $37.40 Consensus PT from Analysts - Defense World
Hsbc Holdings PLC Invests $188,000 in Summit Therapeutics Inc. (NASDAQ:SMMT) - Defense World
Shareholders that lost money on Summit Therapeutics Inc.(SMMT) should contact Levi & Korsinsky about Securities Fraud InvestigationSMMT - ACCESS Newswire
Summit Therapeutics (NASDAQ:SMMT) Upgraded at TD Cowen - Defense World
Shareholders that lost money on Summit Therapeutics Inc. (SMMT) should contact Levi & Korsinsky about Securities Fraud InvestigationSMMT - ACCESS Newswire
Summit Therapeutics Q1 2025 slides: Strong cash position supports advancing Ivonescimab pipeline - Investing.com Canada
SMMT ALERTLevi & Korsinsky Has Commenced an Investigation on Behalf of Summit Therapeutics Inc. Shareholders Who Lost Money - ACCESS Newswire
Why Recursion Pharmaceuticals Stock Plummeted 24% This Week - The Motley Fool
Summit Therapeutics Inc. (SMMT): Among the Best Cancer Stocks to Invest in for Long-Term Gain - Insider Monkey
Summit Therapeutics (SMMT) Receives Positive Coverage from TD Co - GuruFocus
Summit Therapeutics (SMMT) Receives Positive Coverage from TD Cowen | SMMT Stock News - GuruFocus
Summit Therapeutics stock rating upgraded to Buy at TD Cowen By Investing.com - Investing.com India
Summit Therapeutics stock rating upgraded to Buy at TD Cowen - Investing.com
Can Summit Therapeutics Stock Double Your Money? - Nasdaq
Wall Street Analysts Predict a 33.4% Upside in Summit Therapeutics (SMMT): Here's What You Should Know - Yahoo Finance
(SMMT) Trading Advice - news.stocktradersdaily.com
Summit Therapeutics Retail Traders Stoked As Stock Surges On Promising Cancer Drug Trial - MSN
Summit Therapeutics Q1 Loss Narrower Than Expected, Sales Nil - MSN
Why Summit Therapeutics Inc. (SMMT) Soared Last Week - Insider Monkey
These 10 Firms Soared Last Week, Here’s Why - Insider Monkey
Summit Therapeutics outlines ivonescimab progress with key Phase III data expected mid-2025 - MSN
Summit Therapeutics (SMMT) Stock: Goldman Sachs Raises Price Target | SMMT Stock News - GuruFocus
Summit Therapeutics: Promising Clinical Developments and Financial Stability Drive Buy Rating - TipRanks
Decoding Summit Therapeutics Inc (SMMT): A Strategic SWOT Insigh - GuruFocus
Summit Therapeutics Inc. (NASDAQ:SMMT) Q1 2025 Earnings Call Transcript - Insider Monkey
This Soaring Stock Just Delivered More Good News. Time to Buy? - The Globe and Mail
Summit Therapeutics (SMMT) Advances with Ivonescimab in Key Tria - GuruFocus
Summit Therapeutics Reports Q1 2025 Progress and Financials - TipRanks
Summit Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Press Release Distribution & PR Platform - ACCESS Newswire
Summit Therapeutics (SMMT) Beats Q1 Earnings Expectations - GuruFocus
Summit Therapeutics Inc Reports Q1 2025 EPS of $(0.09), Aligning with Estimates; Revenue Unreported - GuruFocus
Summit Therapeutics Reports Q1 2025 Financial Results - TipRanks
Summit Therapeutics Reports Financial Results and Operational Pr - GuruFocus
Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2025 | SMMT Stock News - GuruFocus
Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2025 - Business Wire
Summit Therapeutics (SMMT) Sees Balanced Options Activity Ahead - GuruFocus
Summit Therapeutics Inc Azioni (SMMT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
17.27%
1.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):